rituximab is a relatively novel medication for immunomodulation in current clinical practice . with its use becoming fairly widespread and newer indications being approved at a fast rate it is also imperative to watch for any adverse reactions , which may need monitoring parameters during therapy
a 54-year - old man was diagnosed with limited form of wegener 's granulomatosis 1 year before the current hospitalization .
currently , four adverse effects that warrant a " black box " warning in the package insert are known : infusion reactions , tumor lysis syndrome , mucocutaneous reactions , and progressive multifocal leukoencephalopathy .
rituximab , the first monoclonal antibody approved by the united states food and drug administration ( fda ) for the treatment of malignant disease , is being used to treat a wide variety of conditions in modern practice , including non - hodgkin 's lymphoma , wegener 's granulomatosis , rheumatoid arthritis , thrombotic thrombocytopenic purpura , among many others .
complete atrioventricular block induced by rituximab monotherapy in an 83-year - old has also been described in literature .
ventricular tachycardia during the infusion of rituximab and prompt disappearance after discontinuation of infusion was first reported in 2005 .